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Abstract 
Background To date, no validated risk scores exist for prediction of recurrence risk or 
potential treatment effect for older people with a history of a cardiovascular event. Therefore, 
we assessed predictive values for recurrent cardiovascular disease (CVD), of models with age 
and sex, traditional cardiovascular risk markers, and ‘SMART risk score’, all with and 
without addition of N-terminal pro-B-type natriuretic peptide (NT-proBNP). Treatment effect 
of pravastatin was assessed across low and high risk groups identified by the best performing 
models.  
Design and methods Post-hoc analysis in 2348 participants (age 70-82 years) with a history 
of CVD within the PROspective Study of Pravastatin in the Elderly at Risk (PROSPER) 
study. Composite endpoint was a recurrent cardiovascular event/cardiovascular mortality.  
Results The models with age and sex, traditional risk markers and SMART risk score had 
comparable predictive values (area under the curve (AUC) 0.58, 0.61 and 0.59, respectively). 
Addition of NT-proBNP to these models improved AUCs with 0.07 (pdiff=0.003), 0.05 
(pdiff=0.009) and 0.06 (pdiff <0.001), respectively. For the model with age, sex and NT-
proBNP, the hazard ratio for the composite endpoint in pravastatin users compared to placebo 
was 0.67 (95%CI 0.49-0.90) for those in the highest third of predicted risk and 0.91 (0.57-
1.46) in the lowest third, number needed to treat 12 and 115 (pdiff=0.038) respectively.  
Conclusion In secondary cardiovascular prevention in old age addition of NT-proBNP  
improves prediction of recurrent CVD, cardiovascular mortality and treatment effect of 
pravastatin. A minimal model including age, sex and NT-proBNP predicts as good as 
complex risk models including NT-proBNP.  
 
Keywords 
Aged, Cardiovascular disease, Pro-brain natriuretic peptide, Hydroxymethylglutaryl-CoA 
reductase inhibitors, risk factors, secondary prevention 
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Introduction 
Persons with known cardiovascular disease are at high risk of recurrent events, and guidelines 
worldwide advise statins for secondary prevention,1-3 even in old age.4 Yet, prescription of 
secondary preventive treatment decreases with age.5, 6 This might be caused by dilemmas 
regarding starting, continuing, or safely stopping preventive treatment, as physicians have to 
weigh postponed benefit versus current harm and priorities of care in old age. As many more 
patients are surviving their initial cardiovascular event, prediction of recurrent events 
becomes increasingly important. Ideally, the risk markers or risk models used, not only 
predict recurrence risk, but predict treatment effect as well. In secondary prevention in old 
age, traditional cardiovascular risk markers loose predictive value7, 8 and most risk scores are 
either too complex or only apply to restricted subgroups of hospitalized patients.9-12 To date, 
for the general older population, no risk scores for prediction of recurrence risk and/or 
treatment effect exist. Recently the SMART risk score was developed to predict recurrent 
cardiovascular events in a younger cohort of patients with a history of cardiovascular disease 
(mean age 60 years),13 but this risk score has not been validated in older age.  
 
A new promising predictor of cardiovascular risk in old age is N-terminal pro-brain 
natriuretic peptide (NT-proBNP),8, 14-17 a polypeptide released in reaction to myocardial wall 
stress or ischemia. Addition of NT-proBNP to a model with the traditional cardiovascular risk 
markers or SMART risk score might improve predictive performance, especially in older 
patients.  
 
Therefore, we first validated the SMART risk score in 1157 old subjects (mean age 75 years, 
placebo group) with a history of cardiovascular disease participating in the PROspective 
Study of Pravastatin in the Elderly at Risk (PROSPER).18 We compared the predictive value 
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for recurrent cardiovascular events and mortality of the SMART risk score, with a model 
with traditional cardiovascular risk markers and with a minimal model including only age and 
sex. Second, we investigated whether addition of NT-proBNP to these prediction models 
could improve prediction. Third, we studied whether treatment effect of pravastatin was 
different across groups with low and high risk, calculated with the best performing models. 
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Methods 
Study design 
Data in this study were obtained from the PROSPER study, a randomized, double-blind, 
placebo-controlled trial designed to investigate the effect of pravastatin in prevention of 
vascular events in older persons. Details of the design and outcome of PROSPER have been 
published elsewhere.18-20 Between December 1997 and May 1999, a total of 5804 individuals 
were screened and enrolled in Scotland, Ireland and the Netherlands. Men and women aged 
70-82 years were recruited. A total of 2565 participants had a history of cardiovascular 
disease (including stable angina, intermittent claudication, stroke, transient ischemic attack, 
myocardial infarction and vascular surgery), and were included in the present study. (Flow 
chart provided as supplemental file 1) 
 
Individuals with congestive heart failure (New York Heart Association functional class III 
and IV) or poor cognitive function (Mini-Mental State Examination score <24 points) were 
excluded from PROSPER.20 Participants were randomized into a group who received 40 mg 
pravastatin a day and a control group receiving placebo and were followed 3.2 years on 
average. Throughout the study, all study personnel was unaware of the allocated study 
medication status of the participants. The institutional ethics review boards of all centres 
approved the protocol and all participants gave written informed consent. The protocol 
adhered to the principles of the Declaration of Helsinki. 
 
Traditional cardiovascular risk markers and SMART risk score variables 
During the pre-randomization visits, baseline participant characteristics were collected,19 
including a detailed medical history with date(s) of last cardiovascular events, smoking status 
and current medication use. Participants weight, height and blood pressure were measured 
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and fasting venous blood samples were taken including biobank samples. A history of 
diabetes was defined as a known diabetes mellitus or fasting blood glucose >7 mmol/L. 
Baseline serum creatinine levels were measured at central laboratories. Estimated glomerular 
filtration rate (eGFR) was estimated using the Modification of Diet in Renal Disease 
equation:21 
eGFR=186 x serum creatinine level (mg/dl)(-1.154) x age(-0.203) x 0.742 [if female].  
Data of eGFR was missing for 5 included participants. High sensitivity C-reactive protein 
(hsCRP) levels were measured on stored K2EDTA (at -80ºC) baseline samples.
22 Data of 
hsCRP was missing for 41 included participants. All laboratory analyses were conducted by 
technicians blind to the identity of samples and outcomes. Time since first cardiovascular 
event was calculated from the recorded date(s) of last cardiovascular event.  
 
NT-proBNP measurements 
Blood samples were taken at 6 months after baseline in EDTA tubes.20 The venous blood 
samples were stored in the biobank. From biobank samples NT-proBNP was determined 
using electrochemiluminescence immunoassay on a Roche Modulator E170. NT-proBNP 
measurements were missing for 167 participants due to technical problems.  
 
Outcomes 
For the present study the primary outcome of the trial was used: the combination of definite 
or suspect death from coronary heart disease, non-fatal myocardial infarction and fatal or 
non-fatal stroke.20 The PROSPER Endpoints Committee assessed all endpoints. The 
Endpoints Committee was blinded for study medication, and for plasma levels of NT-
proBNP.  
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Statistical analysis 
From the 2565 participants with a history of cardiovascular disease, participants with 
coronary events or who died in the first 6 months of the study (n=50) and participants with 
missing NT-proBNP values at 6 months (n=167) were excluded. Baseline summary 
characteristics are reported as median with interquartile range (IQR) for continuous variables 
and as numbers with percentage (%) for categorical variables for all participants (n=2348) 
and for participants on placebo and those on pravastatin separately. Follow-up for the 
outcomes was calculated from 6 months onward up to a maximum of 2.5 years. 
 
Calibration of the SMART risk score 
For calculation of the SMART risk score the SMART formula13 was used (Supplemental file 
2). We used complete case analysis. Calibration of the SMART risk score for the PROSPER 
trial population was investigated by comparing the predicted versus observed cardiovascular 
disease risks. Participants taking placebo were divided into five categories of 2.5-year 
predicted risk, <10%, 10 to <20%, 20 to <30%, 30 to <40%, and ≥40%. Within each 
category, predicted risk was compared to actual observed Kaplan-Meier cardiovascular 
disease free survival at 2.5 year follow-up (Supplemental file 3). In addition, the fitted 
regression coefficient (beta) was assessed in a Cox proportional hazard model fit, using only 
the linear prognostic score (A) as variable.23 The continuous predictive SMART prognostic 
risk score was multiplied with the calculated regression coefficient to recalibrate the SMART 
risk score for the PROSPER population, as the calibrated regression coefficient significantly 
differed from 1 (0.466, p<0.001).  
 
Risk prediction with three models in the placebo group 
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The 2.5-year cardiovascular disease risk (%) was predicted for all participants using a Cox 
proportional hazards models (complete case analysis) fit based on 1) age and sex (minimal 
model); 2) age, sex, smoking, systolic blood pressure, high density lipoprotein and total 
cholesterol, history of diabetes, history of hypertension, history of myocardial infarction, 
history of stroke/transient ischaemic attack and history of surgery for peripheral artery 
disease (all as assessed at baseline; traditional model); and 3) recalibrated SMART risk score 
(SMART model). Using the continuous predicted risks from the three models, area under the 
curves (AUCs) and receiver operating characteristic (ROC) curves with p-values (level of 
significance 5%) and 95% confidence intervals for difference were calculated.  
 
Additional value of NT-proBNP in the placebo group 
NT-proBNP was non-normally distributed and therefore log transformed. Cox proportional 
hazards models for the occurrence of the primary endpoint were fitted based on three 
additional models including 1) minimal model plus NT-proBNP; 2) traditional model plus 
NT-proBNP; and 3) SMART model plus NT-proBNP. AUCs and ROC curves were 
calculated and compared to the reference models without NT-proBNP (STATA 12.1). Cross 
validation using the Jack-knife method, was used for comparison of optimism-corrected 
estimates.24  
 
Net Reclassification Improvement  
We calculated the category-less Net Reclassification Improvement (NRI) for the primary 
endpoint with logistic regression, comparing the three models with NT-proBNP models to the 
reference models without NT-proBNP.25, 26  
 
Treatment effect comparing placebo and treatment group 
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Predicted risk for the primary endpoint was calculated for all participants using the regression 
coefficients from the models developed in the placebo group. The treatment effect of 
pravastatin according to the thirds of predicted risk for the primary endpoint of the three 
models including NT-proBNP was assessed in three ways. First, the presence of 
multiplicative interaction was tested by adding the interaction term ‘treatment x thirds of 
predicted risk’ in the Cox model. Second, per third of predicted risk, the absolute numbers of 
events in the pravastatin group and the placebo groups were calculated and the absolute risk 
reduction (ARR) by pravastatin was calculated using the life-table method. Differences in 
ARR between the thirds of predicted risk, were tested using a z-test. Numbers needed to treat 
(NNT) were calculated over 2.5 years based on the difference in cumulative proportion 
surviving in the pravastatin and placebo groups. Finally, the hazard ratio (HR) for the 
occurrence of cardiovascular events in the pravastatin group versus placebo group was 
calculated using the Cox proportional hazard model per third of predicted risk.  
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Results 
Table 1 presents the baseline characteristics for the participants. Of the 2348 participants 57% 
(n=1334) were men, 73% (n=1713) had a history of cardiac disease, 25% (n=594) had a 
history of cerebrovascular disease and 17% (n=408) had a history of peripheral disease. The 
median NT-proBNP level was 176 ng/L (IQR 96-359).  
 
Traditional cardiovascular risk markers and SMART risk score  
During the maximum follow-up of 2.5 years, 16% (n=187) of participants in the placebo 
group (n=1157) developed a cardiovascular event or died of cardiovascular disease (primary 
endpoint). During follow up 147(12.7%) patients developed a coronary event and 43(3.7%) a 
fatal or non-fatal stroke.  
We calculated AUCs and created ROC curves for the minimal model, the traditional model 
and the SMART model, with the primary endpoint at 2.5-year (Figure 1). The three models 
had similar AUCs: 0.58 (95% CI 0.54-0.63) for the minimal model; 0.61 (95%CI 0.57-0.66) 
for the traditional model; and 0.59 (95% CI 0.54-0.63) for the SMART model (Table 2).  
 
Addition of NT-proBNP 
Figure 1 shows that the addition of NT-proBNP improved the AUC of all three models 
similarly. Addition of NT-proBNP to the minimal model increased the AUC from 0.58 to 
0.65 (95% CI 0.6-0.70), Δ 0.07, p for difference (pdiff) =0.003. The increase in AUC was 
similar for both the traditional and the SMART model (Δ 0.05, pdiff=0.009 and Δ 0.06, 
pdiff<0.001, respectively) (Table 2).  
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The minimal model with addition of NT-proBNP performed similarly to the traditional model 
with addition of NT-proBNP (pdiff=0.26) as well as to the SMART model plus NT-proBNP 
(pdiff =0.87).  
 
Cross validation of the minimal model led to an AUC of 0.56 (95% CI 0.52-0.61) and for the 
minimal model with addition of NT-proBNP to an AUC of 0.64 (95% CI 0.60-0.69). The 
difference between these two cross validated AUCs was 0.08 (p=0.0016). Cross validation of 
the other models showed similar results (data not shown).  
 
NRI 
The category-less NRI with addition of NT-proBNP to the minimal model was 41% 
(p<0.001, 57.2 % of participants reclassified up minus 42.8% reclassified down in the group 
that experienced the endpoint, plus 63.2% reclassified down minus 36.8% reclassified up in 
the group that did not experience the endpoint). The category-less NRI with addition of NT-
proBNP to the traditional model was 39% (p<0.001). Addition of NT-proBNP to the SMART 
model had an NRI of 25% (p=0.002) (Table 2). 
 
Treatment effect 
Overall, in the 2348 participants with a history of cardiovascular disease within the 
PROSPER study population, the ARR by pravastatin treatment was 3.6% for 2.5 year. After, 
the 2.5-year HR for the development of the primary endpoint was 0.77 (95% CI 0.62-0.95) in 
the pravastatin group compared to the placebo group.  
 
We divided participants according to thirds of predicted risk. Multiplicative interaction 
between treatment and thirds of predicted risks of all models was not significant (all p>0.1). 
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Table 3 shows the treatment effect (2.5-year) of pravastatin according to thirds of predicted 
risk of cardiovascular disease and mortality for three risk models, all with NT-proBNP, 
including number of events (primary endpoint), ARR and HR. The ARR in primary endpoint 
with 2.5-year pravastatin treatment in the low predicted risk group of the minimal model plus 
NT-proBNP was 0.87% (95% CI -3.2-4.9) and in the high predicted risk group 8.2% (95% CI 
2.6-13.9), difference=7.4% (95% CI 0.43-14.3, pdiff =0.038). (Figure 2) In this model, 
participants with the highest predicted risk (highest third) and pravastatin treatment had a HR 
of 0.67 (95% CI 0.49-0.90) for the development of the primary endpoint compared to those 
on placebo. The NNT during 2.5 years with pravastatin was 12 (95% CI 7-38). HR for 
participants in the lowest third of predicted risk was 0.91 (95% CI 0.57-1.46), with a NNT of 
115 (95% CI 20-∞).  
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Discussion 
This study shows that the predictive value of traditional cardiovascular risk markers and the 
(recalibrated) SMART risk score is poor in older people with a history of cardiovascular 
disease, and comparable to prediction with a model including only age and sex. Addition of 
NT-proBNP, however, improved prediction of recurrent cardiovascular disease and mortality. 
We observed that a model with age, sex and NT-proBNP predicts as good as more complex 
risk models including NT-proBNP. Moreover in high risk individuals as identified by age, 
sex plus NT-proBNP level, NNT for 2.5-year pravastatin treatment was 12, whereas, in 
patients with a low predicted risk in this model, NNT was 115. As many more patients are 
surviving their initial cardiovascular event, prediction and prevention of recurrent events 
becomes increasingly important. According to this study NT-proBNP is a promising risk 
predictor in old age.  
 
Comparison with the literature 
The combination of prediction of recurrent events and treatment effect has seldom been 
examined in secondary cardiovascular prevention. Our findings contrast with the findings in 
the CORONA and Heart Protection Study in patients with chronic heart failure, where the 
benefit of rosuvastatin was higher in the low NT-proBNP group. However, this relationship 
might have been modified by other patient characteristics in this specific population of 
ischemic heart failure patients.27  
Previously, Sattar et al. have investigated within the entire PROSPER study population 
whether hsCRP could predict treatment effect and they observed that hsCRP did not predict 
response to statin therapy.22 In contrast, Drewes et al. found a positive relation of 
homocysteine levels with treatment effect.28 However, physicians are perhaps more inclined 
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to determine serological biomarkers that have a direct association with cardiac strain such as 
NT-proBNP.  
 
With regard to prediction of recurrent events, the predictive value of NT-proBNP has been 
described in primary as well as in secondary prevention,14 even in very old age8, 15, 17 and in 
persons with29 and without clinical heart failure.30 In the literature, addition of NT-proBNP to 
traditional cardiovascular risk markers results in an improvement of the AUC ranging from 
0.01-0,1.8, 14, 31 The HOPE study findings31 showed that of all biomarkers added to traditional 
risk markers in secondary prevention, NT-proBNP was the strongest (increase in AUC 0.05 
as compared to traditional risk markers, p<0.001). This is consistent with the present study in 
a secondary prevention population. The SMART risk score, which includes hsCRP, was not 
superior to the model including age and sex. This might be explained by the decreasing 
predictive value of hsCRP with age,32, 33 as our study population was older by around 15 
years on average, than the population in which the original SMART risk score was 
developed. Also, even if the true risks are the same in both populations, shrinkage can be 
expected when a prediction model is validated in a different population.  
 
Implications for clinical practice and future research 
In our cohort of older persons the SMART risk score had to be recalibrated as it 
overestimated actual risk for recurrent cardiovascular disease and cardiovascular mortality, 
especially in persons assigned to the high risk category. Physicians should be aware of the 
derivation cohort characteristics, before applying new risk scores to their patients.  
 
Our result suggest than in secondary cardiovascular prevention in old age, measuring NT-
proBNP helps physicians better estimate recurrence risk. An additional advantage might be 
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that a high NT-proBNP level prompts clinicians to actively search for signs and symptoms of 
heart failure or (paroxysmal) atrial fibrillation.34 More complex models are not required as 
predictive value was the same as in a model with age and sex only. However this requires 
validation and subsequent evaluation of clinical impact, especially regarding treatment effect, 
before it can be implemented. Nevertheless, the wide availability of NT pro-BNP assays in 
routine laboratories means clinical translation of our findings is ultimately possible. When in 
doubt whether or not to start, stop or continue secondary preventive treatment with statins in 
old age, measurement of NT-proBNP can help clinicians and patients to estimate future risk 
and expected treatment effect. A simple risk prediction model with only a few risk markers 
(age, sex and NT-proBNP)  is easy to use in clinical practice and seems appropriate.   
 
Future etiological studies are necessary to establish the possible causal associations between 
NT-proBNP and cardiovascular and cerebrovascular morbidity and mortality. 
 
Strengths and Limitations 
To analyse NT-proBNP levels in the large well-defined secondary prevention population 
within the PROSPER study population, and to calculate treatment effect accordingly, was a 
tempting opportunity, since placebo controlled RCT’s concerning treatment effect of statins 
are ethically impossible to perform in the present era.  
PROSPER is a randomised controlled trial, therefore, the participants were selected using 
more strict criteria than in a cohort study, like the SMART study. A potential limitation in 
this respect is the exclusion of persons with clinical heart failure or poor cognitive function. 
The observed risks could have been influenced. NT-proBNP was measured at 6 months, not 
at baseline due to limited plasma availability in the latter. Therefore, follow-up was 
calculated from 6 months onward. Pravastatin treatment had no effect on NT-proBNP levels 
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in the first 6 months, which is in line with previous studies.35 Since NT-proBNP was 
measured at 6 months from baseline, we had to exclude participants that already died or 
experienced a cardiac event in the first 6 months of the study (2% of the study population). 
As these participants are likely to be high risk individuals in the models, exclusion may have 
led to an underestimation of the true magnitude of predictive value of the models. It is also a 
limitation that cholesterol, CRP and eGFR  were measured at baseline and not measured at 
six months (like NT-proBNP), as values of cholesterol, CRP and eGFR  might have changed 
in this 6 month period. However, the use of cholesterol levels measured at month six would 
be inappropriate since the pravastatin treatment changes the cholesterol level and would 
therefore lead to incorrect results in the evaluation of the treatment effect.   
Finally, the relatively low AUCs might be considered as a limitation. However, an AUC 
between 0.65 and 0.70 is common in studies in older populations.8, 36  
 
Conclusions 
Due to increased survival following an acute cardiovascular event, also in old age, adequate 
prediction of recurrent events is becoming increasingly important. According to this study 
NT-proBNP is a promising risk predictor. Addition of NT-proBNP to (traditional) risk 
models improves prediction in old age. Moreover, a minimal model with only age, sex and 
NT-proBNP is as good as complex risk models including NT-proBNP.  
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Figure legends 
 
Figure 1. Receiver operating characteristic curves for three models without NT-proBNP 
(dotted lines) and with NT-proBNP (black lines) for cardiovascular events and cardiovascular 
mortality. Model with age and sex (left, minimal model) model with traditional risk markers 
(middle, traditional model) and model with SMART risk score (right, SMART model) (p Δ 
0.003, 0.003 and< 0.001, respectively) 
 
Figure 2. Absolute risk reduction (ARR) and number needed to treat to benefit (NNTB) and 
number needed to harm (NNTH) with pravastatin for 2.5 years, according to tertiles of 
predicted risk, p-value of difference between lowest and highest predicted risk group for 
NNTB, estimated using z-test 
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Table 1 Baseline characteristics of the participants stratified for placebo and 
pravastatin group  
 
 
Total group 
n=2348 
Placebo 
n=1157 
Pravastatin 
n=1191 
Age (years) 75 (73-78) 75 (73-78) 75 (73-78) 
Male Sex 1334 (57) 658 (57) 676 (57) 
Current smoker 427 (18) 214 (19) 213 (18) 
Systolic blood pressure (mmHg) 152 (138-168) 151 (136-168) 153 (138-168) 
High-density lipoprotein cholesterol 
(HDL, mmol/L) 
1.2 (1.0-1.4) 1.2 (1.0-1.4) 1.2 (1.0-1.4) 
Total cholesterol (mmol/L) 5.6 (5.0-6.3) 5.6 (5.0-6.2) 5.6 (5.0-6.3) 
History of diabetes mellitus 200 (9) 99 (9) 101 (9) 
History of coronary artery diseasea 1713 (73) 831 (72) 882 (74) 
History of myocardial infarction 701 (30) 365 (32) 336 (28) 
History of cerebrovascular diseaseb 594 (25) 299 (26) 295 (25) 
History of peripheral artery diseasec 408 (17) 204 (18) 204 (17) 
History of surgery for peripheral 
artery disease  
113 (5) 53 (5) 60 (5) 
Time since first diagnose of 
cardiovascular disease 
6.0 (3.0-11.0) 6.0 (3.0-11.3) 7.0 (3.0-11.0) 
Creatinine clearanced 52 (43-63) 52 (43-63) 52 (43-63) 
High-sensitivity C-reactive protein 
(mg/L)e 
3.1 (1.6-6.3) 3.1 (1.7-6.1) 3.2 (1.6-6.5) 
N-terminal pro-brain natriuretic 
peptide (ng/L)f 
176 (96-359) 174 (96-354) 177 (95-367) 
Data are presented as median with interquartile range (IQR) for continuous variables and as numbers with 
percentage (%) for categorical variables 
a history of angina, myocardial infarction, coronary artery bypass surgery or percutaneous transluminal coronary 
angioplasty 
b history of transient ischemic attack or stroke 
c history of claudication or surgery for peripheral disease  
d calculated with the Cockroft-Gault formula , missing n=5 
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e missing n=41 
f measured at 6 months after study entrance  
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Table 2 Absolute number of events in tertiles of predicted risk of the different models, with area under the curve (AUC), delta AUC 
(ΔAUC ) with addition of NT-proBNP, and category free net reclassification improvement (NRI) for the primary endpoint in the 
placebo group (n=1157) 
Risk models Absolute numbers of events in tertiles of 
risk 
AUC (95%CI) ΔAUC p Δ NRI (%) p value 
 Low  Medium  High       
Minimal model 43 (11.2) 68 (17.8) 76 (19.4) 0.58 (0.54-0.63)     
Minimal model 
plus NT-proBNP 
37 (9.5) 54 (13.7) 96 (25.7) 0.66 (0.61-0.70) 0.07 0.0026 41 <0.001 
         
Traditional model 42 (11.0) 56 (14.6) 89 (22.7) 0.61 (0.57-0.65)     
Traditional model 
plus NT-proBNP 
35 (9.0) 54 (13.7) 98 (26.1) 0.66 (0.62-0.70) 0.05  0.0091 39 <0.001 
         
SMART model 60 (15.8) 60 (16.0) 65 (16.9) 0.59 (0.54-0.63)     
SMART model 
plus NT-proBNP 
53 (14.4) 65 (16.0) 67 (18.3) 0.65 (0.61-0.70) 0.06 0.0006 25 0.002 
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Table 3 Treatment effect after 2.5-year of treatment with pravastatin according to tertiles of predicted risk of cardiovascular disease 
and mortality for three risk models including NT-proBNP 
 Events in pravastatin 
group 
Events in placebo 
group 
ARR (95%CI) HR 
Minimal model plus NT-proBNP     
 Low 34 (8.7) 37 (9.5) 0.87 (-3.2-4.9) 0.91 (0.57-1.46) 
 Medium 42 (10.8) 54 (13.7) 2.9 (-1.8-7.5) 0.78 (0.52-1.17) 
 High 74 (18.0) 96 (25.7) 8.2 (2.6-13.9) 0.67 (0.49-0.90) 
Traditional model plus NT-proBNP     
 Low 26 (6.6) 35 (9.0) 2.5 (-1.28-6.33) 0.73 (0.44-1.20) 
 Medium 45 (11.6) 54 (13.7) 2.0 (-2.73-6.77) 0.83 (0.56-1.24) 
 High 79 (19.4) 98 (26.1) 7.2 (1.18-13.29) 0.71 (0.53-0.95) 
SMART model plus NT-proBNP     
 Low 45 (11.3) 53 (14.4) 3.0 (-1.86-7.78) 0.78 (0.52-1.15) 
 Medium 42 (11.6) 65 (16.0) 4.5 (-0.43-9.45) 0.72 (0.49-1.06) 
 High 60 (14.9) 67 (18.3) 4.0 (-1.45-9.43) 0.78 (0.55-1.11) 
ARR, absolute risk reduction 
HR, hazard ratio 
  
28 
 
Figure 1 
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Figure 2 
 
 
